Abstract

BackgroundAntihypertensives (antiHT) and lipid lowering therapies (LLT) prevent cardiovascular disease (CVD) effectively. It has been reported that patients with rheumatoid arthritis (RA) receive suboptimal CVD-prevention, possibly contributing to their increased...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases
Gunnstein Bakland ... Dag Magnar Soldal
International Journal of Cardiology | VOL. 274
Gunnstein Bakland, et. al.Gunnstein Bakland ... Dag Magnar Soldal
02 Jul 2018
OP0121 MANAGEMENT OF DYSLIPIDAEMIA AND HYPERTENSION IN PATIENTS WITH RHEUMATOID ARTHRITIS – DATA FROM 19 COUNTRIES
A G Semb ... C S Crowson
-
A G Semb, et. al.A G Semb ... C S Crowson
01 Jun 2020
Factors Associated With Therapeutic Goal Attainment in Patients With Concomitant Hypertension and Dyslipidemia
Ishveen Chopra ... Khalid M Kamal
Hospital Practice | VOL. 42
Ishveen Chopra, et. al.Ishveen Chopra ... Khalid M Kamal
01 Apr 2014
Management of dyslipidaemia and hypertension in patients with rheumatoid arthritis in 19 countries
I Graham ... G.D Kitas
European Heart Journal | VOL. 41
I Graham, et. al.I Graham ... G.D Kitas
01 Nov 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers